- BA: Augustana College, Rock Island, IL (1995), Summa cum laude
- Medical Degree: University of Illinois at Chicago College of Medicine, Rockford, IL (1999)
- Residency: Washington University School of Medicine, St. Louis, MO (2002)
- Infectious Diseases Fellowship:Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, MO (2005)
- MSPH: St. Louis University of Public Health, St. Louis MO (2008)
Erik R. Dubberke, MD, MSPH
Professor of Medicine
- Internal Medicine
- Infectious Diseases
- Alumni Association Academic Achievement Award (2008)
- Fellow, Society for Healthcare Epidemiology of America (2013)
- Fellow, Infectious Diseases Society of America (2015)
- Board Members, National Comprehensive Cancer Center Network (NCCN), Prevention and Treatment of Cancer-Related Infections Guideline Committee (2016-present)
- Best Doctors in America, (2015-present)
- Society for Healthcare Epidemiology of America Mid-Career Scholar Award, (2016)
- Editorial Board, Infection Control and Hospital Epidemiology (2011-2018)
- Peer Reviewer, UpToDate, C. difficile infection (2018-present)
Erik R. Dubberke, MD, MSPH is the clinical director of the Transplant Infectious Diseases consult service, and is an associate hospital epidemiologist at Barnes-Jewish Hospital and medical director of infection prevention and control at Missouri Baptist Medical Center. He is co-chair of the Society for Healthcare Epidemiology of America (SHEA) Prevention Course in Healthcare-Associated Infection Knowledge and Control (Prevention CHKC) program.
Dr. Dubberke specializes in clinical and translational infectious diseases, with a focus on transplant infectious diseases, hospital epidemiology, and Clostridioides difficile infection (CDI). His lab specializes in isolation of C. difficile and antibiotic resistant enteric organisms, which creates the bridge between clinical research design and basic science discovery through collaborations with Carey-Ann Burnham, PhD, and Gautam Dantas, PhD. Dr. Dubberke attends on the transplant infectious diseases service teaching fellows, residents, and students. He also sees patients in the outpatient ID clinic, with a focus on recurrent CDI.
He is currently mentoring, and has successfully mentored, post-doctoral and PhD candidates, fellows, and residents in transplant infectious disease and clinical and translational research.
1. Fishbein SRS, Hink T, Reske KA, Cass C, Struttmann E, Iqbal ZH, Seiler S, Kwon JH, Burnham CA, Dantas G, Dubberke ER. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients. mSphere. 2021 Jan 13;6(1):e00936-20. doi: 10.1128/mSphere.00936-20
2. Kwon JH, Reske KA, Hink T, Jackups R, Burnham CD, Dubberke ER. Impact of an electronic hard-stop clinical decision support tool to limit repeat Clostridioides difficile toxin enzyme immunoassay testing on test utilization. Infect Control Hosp Epidemiol. 2019 Dec;40(12):1423-1426. doi: 10.1017/ice.2019.275. Epub 2019 Oct 24.
3. Rauseo AM, Hink T, Reske KA, Seiler SM, Bommarito KM, Fraser VJ, Burnham CD, Dubberke ER; CDC Prevention Epicenter Program. A randomized controlled trial of Lactobacillus rhamnosus GG on antimicrobial-resistant organism colonization. Infect Control Hosp Epidemiol. 2021 Apr 6:1-7. doi: 10.1017/ice.2021.94